Health Care & Life Sciences » Pharmaceuticals | Coland Holdings Ltd.

Coland Holdings Ltd. | Income Statement

Fiscal year is January-December. All values TWD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
1,857
2,205
2,693
3,270
2,638
2,135
Cost of Goods Sold (COGS) incl. D&A
885
1,123
1,354
1,716
1,412
1,103
Gross Income
971
1,082
1,339
1,554
1,226
1,032
SG&A Expense
741
751
866
1,071
923
903
EBIT
231
332
473
483
303
129
Unusual Expense
-
-
-
-
15
-
Non Operating Income/Expense
193
223
71
15
107
105
Interest Expense
-
-
21
23
21
22
Pretax Income
494
609
557
494
422
222
Income Tax
90
115
163
152
120
90
Equity in Affiliates
12
12
7
3
7
10
Consolidated Net Income
393
482
388
339
295
121
Net Income
355
417
285
250
247
135
Net Income After Extraordinaries
355
417
285
250
247
135
Net Income Available to Common
355
417
285
250
247
135
EPS (Basic)
5.05
5.34
3.67
3.24
3.20
1.75
Basic Shares Outstanding
70
78
78
77
77
77
EPS (Diluted)
5.01
5.27
3.67
3.23
3.19
1.75
Diluted Shares Outstanding
71
79
78
77
77
77
EBITDA
262
379
541
552
371
201
Non-Operating Interest Income
34
16
14
11
5
10
Minority Interest Expense
37
66
103
89
49
13

About Coland Holdings

View Profile
Address
2nd Floor
Shanghai Shanghai
China
Employees -
Website http://www.colandpharma.com
Updated 07/08/2019
Coland Holdings Ltd. engages in the development and sale of pharmaceutical products and medical devices. Its products include generic medicines, traditional Chinese patent medicines, biochemical drugs, and medical equipment. The company also sell orthopedic, dental and ophthalmology medical devices.